key: cord-0733227-yccu3cg7 authors: Pipe, Steven W.; Kaczmarek, Radoslaw; Srivastava, Alok; Pierce, Glenn F.; Makris, Mike; Hermans, Cedric title: Management of COVID‐19‐associated coagulopathy in persons with haemophilia date: 2020-11-20 journal: Haemophilia DOI: 10.1111/hae.14191 sha: bbb60d0baa631240b388a3d2e3c311617c79353f doc_id: 733227 cord_uid: yccu3cg7 INTRODUCTION: The SARS‐CoV‐2 coronavirus‐induced infection (COVID‐19) can be associated with a coagulopathy mainly responsible for pulmonary microvasculature thrombosis and systemic thromboembolic manifestations. The pathophysiology and management of the COVID‐19 coagulopathy are likely more complex in patients with inherited bleeding diseases such as haemophilia. These individuals might indeed present with both bleeding and thrombotic complications and require simultaneous antithrombotic and haemostatic treatments. OBJECTIVE: We propose practical guidance for the diagnosis and management of COVID‐19 coagulopathy in persons with haemophilia. RESULTS: Continuation of regular haemostatic treatment is recommended for ambulatory patients. For patients requiring hospital admission and on replacement therapy with factors VIII or IX concentrates, prophylaxis with concentrates should be intensified according to the risk of bleeding complications and associated with prophylactic doses of LMWH. For patients on nonreplacement therapy, emicizumab should be continued and possibly combined with factor VIII and prophylactic doses of LMWH depending on the risk of bleeding and thrombosis. Dose escalation of LMWH tailored to the risk of thrombosis can be employed but not supported by evidence. CONCLUSIONS: These practical recommendations are based on the current literature on COVID‐19 with its impact on haemostasis, indications and modalities for thromboprophylaxis mainly in nonhaemophilic patients and how that is likely to affect persons with haemophilia in different circumstances. They will need to be tailored to each patient's clinical status and validated in future studies. including maintenance of product supply chains, impact of reduced blood and plasma donations, reduced access to health care facilities and haemophilia treatment centres, postponement of elective surgeries, and negative impacts to clinical research programs. In addition, the cancellation of many in person educational and research exchanges risks compromising the advancement and dissemination of important knowledge about the care of haemophilia and, in particular, guidance on the management of complications from COVID- 19. 2 To date, there is a paucity of publications on the clinical experience of PWHs and COVID-19 [3] [4] [5] [6] [7] . There is no information to suggest that PWHs, including those on prophylaxis with traditional replacement therapy or emicizumab, are at increased risk for infection or for more severe disease unless they have additional well-described comorbidities such as older age (>65 years), pulmonary or cardiovascular disease, hypertension, obesity or diabetes mellitus. However, we now have emerging characterization of a COVID-19-associated coagulopathy (CAC), whose management requires special consideration in PWHs. While many PWHs will develop mild or moderate symptoms of COVID-19, a proportion of those infected go on to exhibit severe inflammatory responses associated with acute lung injury, hypoxemic respiratory failure and related mortality. Thromboinflammation describes the interplay between inflammation and coagulation and is now considered a key driver of this pathology. [8] [9] [10] Those with severe COVID-19 exhibit coagulation abnormalities including increases in procoagulant levels (especially factor VIII, von Willebrand factor, fibrinogen) and elevated D-dimer concentrations, a well-characterized biomarker for thrombotic complications. 11 The concomitant presence of this CAC at presentation and progression over the course of hospitalization has been associated with worsening respiratory status and higher mortality. 12 Notably, this coagulopathy has some features of sepsis-induced coagulopathy/disseminated intravascular coagulopathy (DIC), but the haemorrhagic phenotype typical of hyperfibrinolytic consumptive DIC is rare. Therefore, new terminologies have been created to recognize this unique alteration in haemostasis such as CAC. A common finding is an elevation of the D-dimer concentrations even found in ambulant patients with no clinically obvious or investigation supported thrombosis. This elevation seems to be mainly secondary to intra-pulmonary microvascular thromboses, a frequent manifestation of CAC, initially documented in autopsy studies and more recently in antemortem imaging using the dual energy computed tomography (DECT) technology. [13] [14] [15] [16] The clinical experience has also indicated an increased risk of more common thromboembolic complications in the outpatient setting as well as in hospitalized patients with venous thromboembolism, pulmonary emboli, ischaemic limbs and stroke events. 11 This has prompted consensus guidance on coagulation test surveillance, thromboprophylaxis, choice of anticoagulants and intensity of dosing. Though these guidelines and recommendations will need to be tested and even adapted based on clinical studies, their implementation poses special challenges to PWHs. Previous communication from the WFH COVID-19 Task Force highlighted these coagulation abnormalities with COVID-19 and directed attention towards the need for close laboratory monitoring, the need for factor replacement therapy to facilitate the use of anticoagulants for prophylaxis or treatment, and special considerations for patients on concomitant prophylaxis with emicizumab. The current guidance seeks to expand on the prior guidance based on emerging data on the mechanisms of thromboinflammation with COVID-19 and current approaches in use for the management of hospitalized nonhaemophilia patients. We provide consensus recommendations on management of hospitalized PWHs with special considerations regarding haemostatic correction with concurrent anticoagulation and/or intensive care procedures, and updated details regarding management with concurrent use of emicizumab. Review of the emerging data on the mechanisms of thrombo-inflammation with COVID-19 has identified the following 11,14 : • Exaggerated inflammatory response to the pulmonary alveolar injury characterized by procoagulant effectors a. inflammatory cytokines (eg IL-6) lead to activation of vascular endothelial cells and endothelial injury b. components of neutrophil extracellular traps (NETs), present in thrombi, activate the contact pathway and enhance procoagulant pathways resulting in increased thrombin generation c. polyphosphates activate platelets, mast cells and factor XII in the contact pathway amplifying the intrinsic pathway of coagulation d. serine protease inhibitors (antithrombin, protein C, C1 esterase inhibitor) are decreased e. fibrinolysis is impaired due to elevated PAI-1 levels. 11, 14 Another unique aspect of the pathology of this infection is an endotheliopathy that appears to contribute to the microvascular changes that occur with COVID-19. 15,17 SARS-CoV-2 gains access to cells through the angiotensin-converting enzyme (ACE) 2 that is present on endothelial cells. 18 Ensuing inflammatory cell infiltration, endothelial cell apoptosis and microvascular prothrombotic effects lead to microcirculatory dysfunction and the subsequent clinical sequelae in patients with advancing severe disease. Guidance on the recognition, monitoring and management of CAC has been provided from the International Society on Thrombosis and Haemostasis 19 , the American Society of Hematology 20 , the American College of Cardiology 21 and many others. These recommendations have been taken into account and summarized as follows: 3. Coagulopathy appears to be related to severity of illness and resultant thromboinflammation and not the intrinsic viral activity. 9. Bleeding manifestations are not common despite the coagulopathy. [19] [20] [21] 23 In a recent large study, the overall and major bleeding rates were close to 5% and 2%, respectively. 23 All admitted patients should have baseline coagulation workup including PT, aPTT, fibrinogen, D-dimer and platelet count. Following changes in these values can give important information regarding status of the coagulation system and safety of using anticoagulation (Table 1) . Risk for thrombosis should be assessed in all patients. Several studies have shown among COVID-19-infected ICU patients an increased rate of venous thrombo-embolism (VTE), 24 Haemophilia is characterized by a defect in thrombin generation with resultant reduced fibrin formation. In the case of haemophilia 1. We recommend using standard laboratory assays for recognition and monitoring for CAC with these considerations ( 4. There is emerging evidence for thrombotic complications in patients with COVID-19 and seemingly milder or absent pulmonary manifestations ("COVID toes", stroke) even while under care in the community. These have not been reported in haemophilia patients to date including those on emicizumab prophylaxis. Although we recommend continued vigilance with such symptomatology, there is no basis for which to recommend making changes to haemophilia treatment based on these reports. There is a number of investigational agents that treat haemophilia by rebalancing haemostasis. These include fitusiran (RNA interference knockdown of antithrombin), 38 monoclonal antibodies that block tissue factor pathway inhibitor (TFPI) 39, 40 and SerpinPC, an engineered serine protein inhibitor that targets activated protein C. 41 will also need to be tested and validated or modified based on further studies and data. To achieve this goal, inclusion of all admitted PWHs with COVID-19 in registries, as initiated in many countries, should be strongly encouraged. This manuscript reflects the positions of the different authors. A novel coronavirus from patients with pneumonia in China The COVID-19 pandemic: new global challenges for the haemophilia community Clinical findings in a patient with haemophilia A affected by COVID-19 In-hospital management of persons with haemophilia and COVID-19: practical guidance Confronting COVID-19: issues in hemophilia and congenital bleeding disorders Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation COVID-19 update: Covid-19-associated coagulopathy Coagulation abnormalities and thrombosis in patients with COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy COVID-19 coagulopathy in caucasian patients SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT COVID-19 is, in the end, an endothelial disease Pathological role of angiotensin II in severe COVID-19 ISTH interim guidance on recognition and management of coagulopathy in COVID-19 COVID-19 and its implications for thrombosis and anticoagulation COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study ISTH DIC subcommittee communication on anticoagulation in COVID-19 Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the national institute for public health of the Netherlands Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care Diagnostic values of inflammatory and angiogenic factors for acute joint bleeding in patients with severe hemophilia A Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor viii cofactor function, on coagulation assays Frequency of lupus anticoagulant in Covid-19 patients Lupus anticoagulant and abnormal coagulation tests in patients with covid-19 Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor Thrombosis and coagulopathy in COVID-19: an illustrated review Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab A molecular revolution in the treatment of hemophilia Management of COVID-19-associated coagulopathy in persons with haemophilia All authors conceived the article. SP wrote the first draft. All authors provided critical comments. Final submission was approved by all the authors.